Ad:Business Contacts
Ads:Current issue FRUIT PROCESSINGWorld Of Fruits 2023Our technical book Apple Juice TechnologyFRUIT PROCESSING Online Special: Instability of fruit-based beveragesFRUIT PROCESSING Online Special: Don’t give clogs a chanceOrange Juice ChainOur German magazine FLÜSSIGES OBST

Indena’s Quercefit® is an innovative 100 % food-grade delivery system of quercetin based on Phytosome® technology, which optimises quercetin bioavailability (up to 20 times and in the range of a diet rich in vegetables and fruits) with dose linearity. It has been proven to be an effective natural help to manage early stage conditions of COVID-19, in combination with standard care.

Although the emergency due to the pandemic is luckily decreasing at a global level, COVID-19 continues to be the focus for several scientific analysis. Quercetin Phytosome® has been the object of several human studies in the last two years1 – the most recent one issued in January 20232 – which demonstrated that this ingredient, in combination with standard care, when used in early stage of COVID-19, could aid in ameliorating the early conditions and helps keeping the immune system strong, mildening the symptoms and optimising the timing of molecular test conversion from positive to negative.

The most recent study involved a larger group of subjects (100 subjects consisting of 50 people in the quercetin group and 50 ones in the control group) completing the preliminary data anticipated and published in 2021.

Antonella Riva, Head of Product Innovation and Development & LCM of Indena S.p.A, commenting the study “Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomised clinical trial” by Di Pierro et al., explains: “This randomised clinical trial investigated the possible adjuvant effect of an oral quercetin supplementation in mild to moderately symptomatic COVID-19 outpatients. The results revealed that subjects who received quercetin in addition to standard care, cleared the virus better (tested negative for SARS-CoV-2) and had milder symptoms as compared to the people who received the standard care alone. Moreover, participants in the quercetin group also showed statistically significant improvement in the serum levels of inflammatory biomarker LDH. Also the outcomes of our last study then – adds Riva – suggest possible quercetin supplementation effectiveness in the early-stage mild to moderately symptomatic COVID-19 outpatients and may help in optimising the clearance of the SARS-CoV-2 infection, mildening of the symptoms and modulation/control of the host’s inflammatory response. The study also supports the safety of quercetin supplementation in subjects with COVID-19 which has an unpredictable and complex course and hence may be potentially used as an adjuvant alongside routine care in the management of mild to moderate symptoms of COVID-19”.

“We keep devoting resources to clinical research with the aim to get stronger and stronger scientific evidences about Indena’s ingredients. We’re very happy and proud to see such results from our Quercefit® and to give our contribution in helping people’s health which has had to face one of the most serious pandemics in recent years” adds Stefano Togni, Chief Commercial Officer of Indena S.p.A.

Quercetin, a flavonol not naturally present in the human body, is the most abundant polyphenol in fruits and vegetable and is widely used as a dietary supplement to boost the immune system and in general to promote a healthy condition. Quercetin is characterised by crucial pharmacological properties including, antioxidant and immune-protective effects, which allows it to be a potential candidate to support all unpleasant conditions.

1Di Pierro et al., Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study, International Journal of General Medicine 2021:14 2359–2366. IJGM
Di Pierro et al., Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial, International Journal of General Medicine 2021:14 2807–2816. Rondanelli et al., Promising Effects of 3-Month Period of Quercetin Phytosome® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study 2022: 12 66
2Di Pierro et al., Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial, Front. Pharmacol. 13:1096853. doi: 10.3389/fphar.2022.1096853